• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Compounds of the formula <CHEM> having activity as antihistamine or inhibitors of mediator release from basophils or mast cells.
    公开号:SU1542415A3
    申请号:SU843752788
    申请日:1984-06-15
    公开日:1990-02-07
    发明作者:Девлин Джон；Харгрейв Карл；Барсумян Эдвард；Поссанца Генус
    申请人:Берингер Ингельгейм Лтд (Фирма)；
    IPC主号:
    专利说明:

    X
    "IvO4 ™
    H- ICHiV
    where R, R ,,
    R "
    -hydrogen, trifluoromethyl;
    -hydrogen, halo, methyl, methoxy, methylthio, trifluoromethyl, ethoxycarbonyl, piano;
    -C, -C (a-alkyl, allyl, cyclohexyl, phenyl, unsubstituted or substituted in R, R, n, p, m have the indicated
    meanings
    subjected to interaction with the compound of the General formula
    R3 - N С X,
    where R and X have the indicated meanings, in an environment of a low-boiling organic solvent, followed by isolation of the target product in free form or as a salt of hydrochloric acid.
    ate
    Јъ
    uh
    J
    Ed
     CM
    The invention relates to a process for the preparation of piperazine containing compounds suitable for the treatment of inflammations and immunological and allergic diseases, in particular to a process for the preparation of piperazinyl-containing urea or thiourea derivatives of the general formula
    Riv
    R
    1542415
    shminkl b.
    O (CH2: V N- (CHiV-NH-C-NHR 2 "Niw
    where R, is hydrogen, trifluoromethyl; R. is hydrogen, halo, methyl, methoxy, methylthio, trifluoromethyl, Bonyl ethoxy, cyano;
    R- - C (- („-alkyl, allyl, cyclohexyl, phenyl, unsubstituted or substituted by halogen, lower alkyl, lower alkoxy, carboxyl, lower alkoxycarbonyl, hydroxyl, cyano, nitro, lower alkylthio, sulfamyl or carbamyl;
    X is oxygen or sulfur; p b - 3; m O, 1; Р - 2 - 4, or their salts with hydrochloric acid
    The aim of the invention is to obtain new piperazinyl-containing compounds of the said general formula with improved, antiallergic and inflammatory properties.
    Example 1. β-3-4- (4-chlorobenzyl) piperazin-1- -yl-propyl 3-3-cyclohexylurea dihydrochloride solution 2.0 g (7.5 mmol) of 1- (3-α-aminopropyl) -4- (4- chlorobenzyl) piperazine, 6g (12.8 mmol) of cyclohexylisocyanate in 5 ml of tetrahydrofuran are stirred for 30 minutes at room temperature. The reaction mixture is evaporated under reduced pressure and the remaining oil is dissolved in 10 ml of ethanol. The crude product is precipitated as a white solid by the addition of water, which is collected by filtration and recrystallized twice from cyclohexane. 1.62 g (56%) of 1 -Ј} - Q4- (4-chlorobenzyl) piperazin-1--yl-ylp-3} -3-cyclohexyl moistenes are obtained in the form of a white crystalline solid. Т „pl.„ 109 - 112 ° С.
    The product is dissolved in 20 ml of methylene chloride and precipitated as dihydrochloride by the addition of excess hydrochloric acid. After recoding 1542415
    from the water, the target product is obtained in the form of colorless crystals with mp. 184 - 187 ° C.
    Example 2 1-Hz-Ј4- (4-chlorobenzyl) piperazin-1- -yl propyl-3-methyl urea dihydrochloride.
    A solution of 2.68 g (10 mmol) of 1- (35-aminopropyl) -4- (4-chlorobenzyl) pi-pyrazine and 0.57 g (10 mmol) of methyl isocyanate in 10 ml of methylene chloride is stirred overnight at room temperature. temperature The reaction mixture is evaporated under reduced pressure and the residue is subjected to chromatography on a silica gel-containing column using as eluent a mixture of methanol, hydroxide
    5 aluminum and methylene chloride. Then 1.0 g (31%) of the obtained product is dissolved in 20 ml of a mixture of methylene chloride and ether (1: 1 ratio). The solution is treated with anhydrous hydrogen chloride. Get the target product in the form of colorless crystals. T0 Sq. 193 - 207 ° С.
    Example 3. 1- {3- (4- (4-chlorobenzyl) piperazine-1-igG propyl-3-n-butylurea dihydride dihydride hemihydrate).
    A solution of 2.67 g of 10 mmol of (3-α-aminopropyl) -4- (4-chlorobenzyl) pipa0 Razin in 50 ml of methylene chloride and 1.09 g (11 mmol) of n-butyl isocyanate are heated under reflux for 2 h. . The reaction mixture is concentrated in vacuo and the residue is treated with ethereal hydrogen chloride. Recrystallized from a mixture of methylene chloride and methanol. 3.2 g (71%) of the desired product are obtained in the form of colorless crystals. T. pl.
     222 - 223 ° C.
    Example 4. Dihydrochloride 1 (4-chlorobenzyl) piperazin-1-ylpropyl-3-n-hexyl-moistenes.
     Proceed as described in example 3, using 3.77 g (10 mmol)
    5 1- (3-aminropropyl) -4- (4-chlorobenzyl) piperazine trihydrochloride, 50 ml of tetrahydrofuran, 4.2 ml (30 mmol) of triethylamine and 1.41 g (10 mmol)
    51
    n-hexyl isocyanate. By recrystallization from ethanol, 4.00 g (83%) of the desired product are obtained in the form of colorless crystals, m.p. 214-215 ° C
    Example 5 1-GZ-4- (4-chlorobenzyl) piperazin-1-yl-propyl-3-n-octyl urea dihydrochloride.
    Proceed as described in example 3, using 3.77 g (10 mmol) of 1- (3-aminopropyl) -4- (4-chlorobenzyl) piperazine trihydrochloride, 50 ml of tetrahydrofuran, 4.2 ml (30 mmol) of triethylamine and 1 , 55 g (10 mmol) of n-octyl isocyanate. Recrystallize from a mixture of methanol, ethanol and water. 3.1 g (62%) of the title compound are obtained in the form of white crystals, m.p. 229-230 ° C.
    Example 6. Monohydrate dihydrochloride 1 - | 3-Ј4- (4-fluorobenzyl) piperazin-1-propyl-3-cyclohex from a ylmochine.
    A solution of 2.0 g (8 mmol) of 1- (3-aminopropyl) -4- (4-fluorobenzyl) piperazine and 1.0 g (8 mmol) of cyclohexyl isocyanate in 20 ml of methylene chloride is stirred overnight at room temperature. The reaction mixture is evaporated and the residue is mixed with 20 ml of ether. The ether solution is filtered, the filtrate is subjected to chromatography on a column containing 300 g of silica gel, using the indicated solvent. The fractions containing the product are eluted with a mixture of methylene chloride, methanol and ammonium hydroxide (45: 5: 1 ratio). By evaporation, 2.6 g (85%) of (4-fluorobenzyl) piperazin-1-yl propyA-3-cyclohexyl urea are obtained in the form of a light yellow oil. The product is dissolved in ether, precipitated with ethereal hydrogen chloride and recrystallized from ethanol. 2.96 g (yield 80%) of the title compound T. pl0 203 - 206 ° C is obtained.
    Example 7 1-Ј3- (4-benzylpiperazin-1-yl) dihydrochloride-propyl-3-cyclohexylurea.
    A solution of 2 g (12.9 mmol) of 1- (3-α-aminopropyl) -4-benzylpiperazine and 1.6 g (12.9 mmol) of cyclohexyl isocyanate in 50 ml of methylene chloride is stirred overnight at room temperature. The reaction mixture is concentrated and the crude product as the dihydrochloride precipitate 4224156
    yielded from ether in the manner described in Example 6 was recrystallized from ethanol to obtain 3.62 g (yield 65%) of the title compound as colorless crystals. T, pl. 202 - 213 ° C.
    Example 8. (4-Benzyl-piperazin-1-yl) propyl-3-phenyl-moche 10 wine-. ,
    A solution of 3, 0 g (1 2, 9 mmol) of 1- (3-aminopropyl) -4-benzylpiperazine and 1.54 g (12.9 mmol) of phenyl isocyanate in 20 ml of methylene chloride is sewed overnight at room temperature. The reaction mixture is concentrated under reduced pressure and the residue is crystallized with aqueous acetone. 2.77 g (61%) of a cer2Q left compound are obtained in the form of colorless crystals. T „pl. 45 - 47 ° C.
    Example 9. 1- {3- 4- (4-Chlorobenzyl) piperazin-1-yl propyl-3-phenyl mobide in a.
    25 A solution of 2.0 g (7.5 mmol) of 1- (3-α-aminopropyl) -4- (4-chlorobenzyl) pi-pyrazine and 1.6 g (13.4 mmol) of phenyl isocyanate in 5 ml of tetrahydrofuran is stirred for 30 minutes at
    30 ml of room temperature, 5 ml of ethanol is added, the reaction mixture is stirred for 3 hours and dried under reduced pressure. The residue is crystallized with aqueous ethanol. 2.7 g of crude product is obtained. By recrystallization from the indicated solvent, 0.62-g (yield 21%) of the title compound is obtained as colorless crystals. T. pl.
    35
    135 - 137UC.
    Example 10. Hydrochlorine 1-Јз-4- (4-chlorobenzyl) piperazin-1- -ylpropyl-3- (4-chlorophenyl) urea. Example 3 is repeated using
    2.67 g (10 mmol) of 1- (3-aminopropyl) -4- (4-chlorobeneyl) piperazine, 50 ml of methylene chloride, and 1.54 g (10 mmol) of 4-chlorofenesocyanate. By recrystallization from methanol
    1.1 g (25%) of the title compound are obtained as colorless crystals. T. pl. 241 ° C.
    Example 11 “Monohydrate dihydrochloride of 1 (4-chlorobenzyl) piperazin-1-hydroxy-3- (4-methylphenyl) urine.,
    Proceed as described in example 3, using 2.67 g (10 mmol)
    7
    1- (3-aminopropyl) -4- (4-chlorobenzyl) piperazine, 50 ml of methylene chloride and 1.33 g (10 mmol) of 4-tolyl isocyanate. By recrystallization from a mixture of methanol and methylene chloride, 0.81 g (17%) of the desired compound is obtained in the form of colorless crystals. Mp. 131 - 132 ° С „
    Example 12 Hydrochloride 1-3 -4-4- (4-chlorobenzyl) pipera; 8-1-1-lL propyl-3- (4-methoxyphenyl) urea.
    Proceed as described in example 3, using 0 5.09 g (19 mmol 1- (3-aminopropyl) -4- (4-chlorobenzyl) piperazine, 50 ml of methylene chloride and 2.83 g (19 mmol) of 4-methoxy- phenyl isocyanate. By recrystallization from a mixture of methanol and methylene chloride, 3.57 g (45%) of the desired compound are obtained in the form of orange-white crystals, t „pl., 237 - 238 ° C.
    Example 13. Hydrochloride 1 {3-G4- (4-chlorobenzyl) piperazine -1 - -ylTropsht -3- (4-ethoxycarbonylphenol urea
    Proceed as described in example 3, using 7.54 g (20 mmol) of 1 - (3-aminopropyl) -4- (4-chlorobenzyl) piperazine, 50 ml of methylene chloride, 50 ml of tetrahydrofuran, 8.4 ml (60 mmol) triethylamine and 3.8 g (20 mmol) of 4-ethoxycarbonylphenyl isocyanate. By recrystallization from methanol, 3.11 g (34%) of the title compound are obtained as colorless crystals. The melting point is 233 - 234 ° C.
    Example 14. Monohydrate dihydrochloride of 1-ЈЈ-4- (4-chlorobenzyl) -piperazin-1-shG) propyl 13- (4-fluorophenyl) urea
    Proceed as described in example 3, using 3.77 g 10 mmol) of trihydrochloride 1 - (3-amino propyl) -4- - (4-chlorobenzyl) piperazine, 50 ml of methylene chloride, 10 ml of tetrahydrofuran, 4.2 ml (30 ml) mmol) of triethylamine and 1.37 g of 10 mmol) of 4-fluorine phenyl isocyanate. After recrystallization from a mixture of methanol and methylene chloride, 3.75 g (76%) of the desired compound are obtained in the form of colorless crystals. T pl0 225 - 228 ° C
    PRI m ip 15 Dihydrochloride 1 -Gz-JV (4-chlorobenzyl piperazin-1 - -yl propyl 3- (4-nitrophenyl) urea
    Proceed as described in example 3, using 3.77 g (10 mmol)
    ten
    424158
    1- (3-aminopropyl) -4- - (4-chlorobenzyl) piperazine trihydrochloride, 50 ml of tetrahydrofuran, 4.2 ml (30 mmol) of triethylamine and 1.64 g (10 mmol) of 4- -nitrophenyl isocyanate, after recrystallization from mixtures of methanol and water give 2.79 g (55%) of the desired product as yellow-white crystals. T. plo 230 - 231 C (decomposition).
    Example 16. 1-Hz-4- (4-chlorobenzyl) homopiperazin-1-yl propyl-3-cyclohexylurea dihydrochloride. .Solution of 2.16 g (7.7 mmol) of 1- (3-aminopropyl) -4- (4-chlorobenzyl) homopiperazine in 30 ml of methylene chloride and 1.05 g (8.5 mmol) of cyclohexylisocyanate in for 1 hour
    0 sew at room temperature. The reaction mixture is concentrated under reduced pressure. The resulting oil is subjected to chromatography on a column of silica gel (methylene chloride, methanol, and ammonium hydroxide in a ratio of 97: 2.5: 0.5). 1 (4-chlorobenzyl) homopiperazin-1-yl propyl-3-cyclohexylurea is obtained as a colorless oil. it
    30 The oil is dissolved in ether and precipitated with ethereal hydrogen chloride. 2.25 g (61%) of the title compound are obtained as a white crystalline solid. T0 Sq. 167 - 175 ° C (decomposition).
    Example 17. Dihydrochloride
    1 -Јз-Ј4 - (. 4-chlorobenzyl) homopiperazin-1-propyl-3-phenylmochbvinYo
    1.03 g (3.7 mmol) of 1- (3-amino40 propyl) -4- (4-chlorobenzyl) homopiperazine as described in example 16 for 2 hours is exposed to 0.55 g (4.6 mmol ) phenyl isocyanate in 15 ml of methylene chloride. The crude product is isolated, purified on silica gel and converted into the hydrochloride salt in a similar manner. 1.23 g (83%) of the title compound are obtained as colorless crystals.
    T. pl. 125 - 135 ° C.
    Example 18. (4-Chlorobenzyl) piperazin-1-yl propyl-3-cyclo-ec from a ylmochine.
     5.36 g (20 mmol) of 1- (3-aminopropyl) -4- (4-chlorobenzyl) piperazine are reacted with 2.82 g (20 mmol) of cyclohexyl isocyanate in 35 ml for 2 h in the example described in Example 16. methylene chloride. Raw
    91
    the product is isolated and subjected to silica gel chromatography in a similar manner. After recrystallization from ethanol, 2.98 t (36%) of the title compound are obtained as colorless crystals. T „pl. 127 - 128 ° C,
    Example 19 (4-Chlorobenzyl) piperazin-1-shL propyl V-3-phenylthiourea.
    5.36 g (20 mmol) of 1- (3-aminopropyl) -4- (4-chlorobenzyl) piperazine by the method described in Example 16 is reacted with 2.82 g (21 mmol) of phenyl isothiocyanate. The crude product is similarly isolated and subjected to chromatography on silica gel. After crystallization from ethanol, 2.39 g (30%) of an off-white crystalline solid are obtained. T. pl. 155 - 156 ° C.
    Example 20 1-W-f4- (4-chlorobenzyl) piperaein-1 -yl | propsD-3-n-hexyl-thiourea UH dihydrochloride hemihydrate
    A solution of 1.57 g (10 mmol) of n-hexyl isothio dianate in 100 ml of methylene chloride was slowly added to a solution of 3.77 g (10 mmol) of 1- (3-aminopropyl) -4- (4-chloro-) hydrochloride trihydrochloride. benzyl) piperazine in 100 ml of methylene chloride and 4.3 ml (31 mmol) of triethylamine. The resulting mixture is heated under reflux for 2 hours, washed with aqueous sodium bicarbonate, dried with sodium sulfate, filtered and the salt precipitated with ethereal hydrochloric acid. After recrystallization from ethanol, 0.80 g (16%) of the desired compound is obtained in the form of a whitish powder. , T. square 182 - 186 ° C0
    Example 21. Dihydrochloride - (4-chlorobenzyl) piperazin-1- -pcs) propyl | -3 -b enzylmochine.
    In the manner described in Example 20, 1.33 g (10 mmol) of benzoxisocyanate, 3.77 g (10 mmol) of 1- (3-aminopropyl) -4- (4-chlorobenzyl) piperazine trihydrochloride are used. ml of methylene chloride and 4.3 ml (31 mmol) of triethylamine. 3.65 g (77%) of the title compound are obtained as colorless crystals. T. pl. 203 - 206 ° С
    Example 22. The dihydrochloride) -Gz-Ј4- (4-chlorophenethyl) piperazin--1-yl propyl-3-n-hexylurea.
    Q
    “J 0
    five
    0 o
    five
    Q
    five
    five
    15Y
    A solution of 1.27 g (10 mmol) n-hex. silicisocyanate in 25 ml of methylene chloride was added to a solution of 2.82 g (10 mmol) of 1- (3-aminopropyl) -4- (4-chlorophenyl) piperazine in 50 ml of methylene chloride. The resulting mixture is heated under reflux for 6 hours and concentrated in vacuo. A yellow oil is obtained, which is subjected to chromatography on a silica gel column (methylene chloride, methanol and ammonium hydroxide in a ratio of 45: 5: 1). After precipitation of dihydrocarbonate and recrystallization from ethanol, 0.91 g (19%) of the title compound is obtained. as colorless crystals T0 pl. 230 - 233 ° C.
    Example 23. 1- {3-C4- (4-chlorobenzyl) piperazin-1-shl-prop-D-3- (4-cyanophenyl urea) monohydrate monohydrate.
    Proceed as described in example 20, and using 1.44 g (10 mmol) of 4-cyanophenyl isocyanate, 3.77 g (10 mmol) of 1- (3-aminopropyl) -4- (4-chlorobenzyl) piperazine trihydrochloride, 75 ml of chloride methylene and 4.3 ml (31 mmol) of triethylamine. After recrystallization from a mixture of methanol and ethanol, 3.87 g (77%) of the desired compound are obtained in the form of colorless crystals of a T0 pl. 236 - 238 ° С.
    Example 24 0 1-Hz-Ј4-Ј3- (4-chlorophenyl) propyl-1-dipyrazin-1-propyl-H-3-n-hexyl-1-hydroxy chloride dihydrochloride.
    AO 35 g (35 mmol) of triethylamine is slowly added to a mixture of 39 g (0.3 mol) of chloropropylamine hydrochloride, 38.2 g (0.3 mol) of n-hexyl isocyanate and 500 ml of methylene chloride. The resulting solution was stirred for 1 h and then the solvent was removed in vacuo. The residue was treated with ether and the colorless solid was filtered. The ether solution is washed with water, dried over magnesium sulfate and concentrated. 57.0 g (86%) of pure 1- (3-chloropropyl) -3-n-hexylurea are obtained in the form of colorless crystals. T, pl 48 - 50 ° C.
    B. A mixture of 2.21 g (10 mmol) of 1- (3-chloropropyl) propyl piperazine, 1, 01 g (10 mmol) of triethylamine, and 25 ml of alcohol is heated under reflux for 18 hours. Cooled
    eleven
    The mixture is diluted with ether, washed with water, dried over sodium sulfate and concentrated in vacuo. The resulting yellow viscous oil is purified on a column of silica gel (methylene chloride and methanol in a ratio of 93: 7). The precipitation of ethereal hydrochloric acid gives 1.6 g (38%) of the desired compound in
    as colorless crystals. T. pl. 213 - 216 ° C.
    Example 25. 1- {3- 4- (4-chlorobenzyl) peepazin-1-yl propyl dihydrochloride dihydrochloride-3- (4-acetylfe-
    Nile) urine evins.
    A solution of 1.61 g (10 mmol) of 4-acetylphenyl isocyanate in 1 00 ml of methylene chloride is added to a solution of 3.77 g (10 mmol) of trihydrochloride
    1- (3-aminopropyl) -4- (4-chlorobenzyl) piperazine, 50 ml of methylene chloride and 4.3 ml (31 mmol) of triethyl amnna. The resulting mixture is heated under reflux for 3 hours, washed with aqueous sodium bicarbonate, dried with sodium sulfate and the product precipitated with ethereal hydrochloric acid. After recrystallization from ethanol, 4.13 g (82%) of the title compound is obtained as a white powder. T. pl. 197 ° C (with slow decomposition).
    Example 26. 1-3-Ј4- (4-chlorobenzyl) piperazin-1-yl-propylL-3- (4-ethoxyphenyl) urine dihydrochloride.
    Proceed as described in example 25. The form, and using 1.63 g (10 mmol) of 4-ethoxyphenyl isocyanate, 3.77 g (10 mmol) of 1- (3-aminopropyl) -4- (4-chlorobenzyl) piperazine trihydrochloride, 16 ml methylene chloride and 4.3 ml (31 mmol) of triethyl-amine. . After recrystallization from ethanol, 3.42 g (68%) of the title compound is obtained as colorless crystals. T0 pl, 225 - 227 ° C.
    Example 27. (4-Chlorobenzyl) piperazin-1-shlpropsgt-3-4- (methylthio) phenyl urea monohydrate dihydrochloride.
    Proceed as described in example 25, using J0.0 g (60.5 mmol) of 4- (methylthio) phenyl isocyanate, 22.8 g (60.5 mmol) of 1- (3-aminopropyl) -4- - (4-chlorobenzyl) piperazine, 400 ml of methylene chloride and 25.8 ml
    five
    Q
    5 o
    g
    0
    five
    1512
    (85 mmol) of triethylamine. After recrystallization from a mixture of methanol and water, 27.3 g (89%) of the title compound are obtained as colorless crystals. Mp. 212 - 214 С „
    EXAMPLE 28 1- | 3- (| 4- (4-chlorobenzyl) piperazin-1-yl propyl} -3-Ј4- (methylthio) phenyl urea monohydrate dihydrochloride salt.
    Proceed as described in Example 25 using 1.54 g (10 mmol) of 2-chlorophenyl isocyanate, 3.77 g (10 mmol) of 1- (3-aminopropyl) -4- (4-chlorobenzyl) piperazine J 2 hydrochloride 50 ml methylene chloride and 4.3 ml (31 mmol) of triethylamine. After recrystallization from methanol, 2.63 g (53%) of the title compound are obtained in the form of light-colored crystals. T. pl. 222 - 224 ° C.
    Example 29. 1 -Gz-Ј4- (4-chlorobenzyl) piperazin-1- -yl-propylL-3- (2,6-dichlorophenyl) mrhequine dihydrochloride.
    (
    Proceed as described in example 25, using 1.88 g (10 mmol) of 2,6-dichlorophenyl isocyanate, 3.77 g (10 mmol) of 1- (3-aminopropyl) -4- (4-chlorobenzyl) piperazine trihydrochloride on, 50 ml of methylene chloride and 4.3 ml (31 mmol) of triethylamine. After recrystallization from methanol, 2.75 g (52%) of the title compound are obtained as colorless crystals. T. pl. 246 - 248 ° С.
    Example 30. 1-Hz-4- (4-chlorobenzyl) piperizin-1- -yl-propyl} -3- (n-dodecyl) urea dihydrochloride.
    Proceed as described in example 25, using 2.11 g (10 mmol) of n-dodecylisocyanate, 3.77 g (10 mmol) of 1- (3-aminopropyl) -4- (4-chlorobenzyl) piperazine trihydrochloride, 100 ml of chloride methylene and 3.03 g (30 mmol) of triethylamine. After recrystallization from water, 3.21 g (58%) of the title compound are obtained as colorless red crystals. T. pl. 215 - 222 ° C0
    Example 31. Dihydrochloride (4-chlorbenzyl) sawnane times in-2- -yl-propyl j-3- (4-carbamylphenyl) urea.
    A solution of 10.0 g (19.9 mmol) of 1- {3- 4- (4-chlorobenzyl) piperazin-1 -shy propyl dihydrochloride monohydrate 13
    -3- (4-cyanophenyl) urea, I, 20 ml of glacial acetic acid and 80 ml of concentrated hydrochloric acid are heated at 80 ° C for 30 minutes. The mixture is poured on ice and alkalinized with aqueous potassium hydroxide. The product is extracted with methylene chloride, dried over sodium sulfate, and the salt precipitated with ethereal hydrochloric acid. It is recrystallized several times from ethanol to obtain 3.54 g (38%) of the desired compound as colorless crystals. T. pl. 224 - 226 ° C.
    Example 32. 1- | 3-Ј4- (4-chlorobenzyl) piperazin-1- -yl propyl-3- (4-tert-butylphenyl) urea dihydrochloride.
    A solution of 4.22 g (20 mmol) of 3-iodopropyl isocyanate in 25 ml of ether is added to a solution of 2.98 g (20 mmol) of 4-tert-butylaniline in 25 ml of ether. The resulting solution is heated under reflux for 3 hours. After removal of the solvent, 4.18 (20 mmol) of 4-chlorobenzylpiperazine in 50 ml of ethanol was added. The resulting solution is heated under reflux for 24 hours. Aqueous sodium bicarbonate is added to the mixture and then the product is extracted with methylene chloride, dried with sodium sulfate, and the salt is salted with ethereal hydrochloric acid. After repeated recrystallization with ethanol, 3.73 g (33%) of the title compound are obtained as colorless crystals. T. pl. 240 - 241 ° C.
    Analogously to Examples 1-32, the following compounds were prepared:
    1- 3-Ј4- (4-chlorobenzyl) piperazin-1-yl propyl-3- (4-car-boxyphenyl) urea hydrochloride, tons, 244- 246 ° C, yield 48% (l);
    1 - ((3-trifluoro-methyl-4-chlorobenzyl) piperazin-1 propyl-3-n-hexylurea dihydrochloride, mp 216-219 ° C, yield 35% (ll);
    1-z-4-Ј3- (4-chlorophenyl) propyl 1-pipera-yin-1-yl propyl-3- (4-cyanophenyl) urea dihydrochloride monohydrate, t. 219-221 ° C, yield 29% (III);
    dihydrochloride (4-chlorobenzyl) piperazine-1-pc propyl 3-allyl-urea, so pl. 232-234 ° C, yield 50% (IV);
    4241514
    1 - | 3-G4- (4-chloroben -.- zyl) piperazin-1 yl propyl-3- (3-ethoxycarbonylphenyl) urea dihydrochloride, t „pl. 240-5-243 ° C, yield 34% (V);
    1-Hz-4- (4-chlorobenzyl) piperazine-ShpropYL (3 oxo-4-ethokeicarbonylphenyl) urea dihydrochloride, t. pl. 245-247 ° C, yield 21% (VI); 10 monohydrate dihydrochloride 1- | 3- (4-cyanobenzyl) piperazin-1-shG) - propyl-3- (4-cyanophenyl) urea, t „pl. 220-223 ° C, yield 26% (VII); 1- | 3-H- (4-chloro-15 benzyl) piperazine-1-yl propyl-3- (4-sulfmylphenyl) urea dihydrochloride, t. pl. 245-246 ° C, yield 31% (VIII);
    1- 3-Ј4- (4-cyano-benzyl) piperazin-1-yl propyl} -3- (4-20-ethoxycarbonylphenyl) urea dihydrochloride, t. pl. 241-245 ° C, yield. 46% - (ix);
    1- {3-Ј4- (4-methoxy-sibenzyl) piperazin-1-yl propyl 3- - (4-ethoxycarbonylphenyl urea dihydrochloride, - 25 t „pl. 215-218 ° С, yield 43% (x);
    dihydrochloride monohydrate (4-methylthiobenzyl) piperazin-1-yl-propyl 1-3- (4-ethoxycarbonylphenyl / urea, mp 200-222 C, 39% yield (XI);
    hydrochloride monohydrate 1- | 3- (4-methylbenzyl) piperaein-1 propyl-3- (4-ethoxycarbonylphenyl) 35 urea, mp, 226-229 ° C, yield 37% (XII);
    Dihydrochloride monohydrate -Ј4- (3-trifluoromethylbenzyl) piperazin-1-yl propyl-3- (4-ethoxycarbo-40 nilphenyl) urea, so pl. 240-243 ° C, yield 22% (XIII);
    dihydrochloride monohydrate - 4- (4-ethoxycarbonylbenzyl) piperazin-1 -yl propyl-3- (4-ethoxycar-4 bonylphenyl) urea, t. pl. 235-237 ° C, yield 26% (XIV);
    1- {2- 4- (4-chlorobenzyl) piperazin-1-yl) propyl-3- (4--cyanophenyl) urea dihydrochloride, t mp, 217-50 219 ° C, yield 35% (XV);
    dihydrochloride hemihydrate 1-G4- (4-chlorobenzyl) piperazin-1 butyl-3- (4-ethoxycarbonylphenyl) urea, so pl. 227-228 ° C, yield 39% - (XVI);
    monohydrate dihydrochloride 1- | 3- (4-chlorobenzyl) piperazin-1 -yl propyl | -3- (4-methoxycarbonyl) urea-
    151
    us, t. pl. 205-208 ° C, yield 25% (XVII);
    1- (4- (4-chlorobenzyl) piperazin-1-igH butyl | -3- (4-cyanophenyl) urea dihydrochloride monohydrate, mp 203-212 ° C, yield 42% (XVIII);
    1- {3- (4-chlorobenzyl) piperazin-1-ylD-propyl} -3- (4-oxyphenyl) urine dihydrochloride monohydrate,
    m.p. 224-228 ° C, yield 40% (XIX);
    dihydrochloride (4-hlrr-benzyl Shiperazin-1-propylL-3- (4-isopropoxycarbonylphenyl) urine, mp 230-232 ° C, yield 31%
    (Xx);
    1- {2-. dihydrochloride monohydrate. (4-Chlorobenzyl) piperazin-1-yl-ethyl-3- (4-ethoxycarbonyl) urea, m.p. 218-219 ° C, yield 36% (XXl);
    dihydrochloride monohydrate 1; -Ј} - (4-chlorobenzyl) piperazin-1 -yl D-prop-3- (4-n-butoxycarbonylphenyl) urea, t „pl. 205-207 ° C, yield 32% (XXII); .
    1- {3- (3-chlorobenzyl piperazin-1-yl-propyl | -3- (4-ethoxycarbonylphenyl-urea) dihydrochloride hemihydrate, mn, 230-232 ° C, yield 29% (XXIII).
    The higher activity of the new piperazinyl-containing compounds compared to that of the known compound is confirmed by the results of the experiment on the determination of the concentration that provides 50% inhibition (CT) of the histamine from human leukocytes.
    The results are tabulated.
    sixteen
    Table continuation
    The novel compounds have the same toxicity as the known compound, T0e0 100 mg / kg (oral, mouse). The results / tables indicate a higher antiallergic activity of these compounds. Experience in determining inhibition of histamine release from human leukocytes in a test tube.
    To 1.0 ml of a suspension of human leukocytes (2-U6 cells) in a Tris-AFM buffer system, 0.05 ml of antigen (anti-human immunoassay) is added.
    17154241518
    globulin E) and 0.2 ml of water, containing the active substance from the supernatant, with a greater concentration of 0.2 ml of 8% perchlorine concentration. The reaction mixture is acid. The release of histamine is cubed at 37 ° C for 60 minutes, measured by fluorometry and its percentage, after which it is centrifuged and the suction braking is calculated by the next fluid collected. Protein Formula:
    control medium - Medium with active substance control medium
    The concentration of the active is determined by interpolation by the diagram
    substances that provide 50% inhibitory inhibition and logarithma release of histamine (KTgo), on-concentration of the active substance.
    权利要求:
    Claims (5)
    [1]
    or their salts with hydrochloric acid, characterized in that the compound of the general formula β · Wm where R <, R ^, η, ρ, m have the indicated meanings, are reacted with a compound of the general formula
    R 3 - N = C = X, where R 3 and X have the indicated meanings, in a low-boiling organic solvent, followed by isolation of the target product in free water or in the form of hydrochloric acid salt. The invention relates to a method for producing piperazine-containing soy- movements suitable for the treatment of inflammations and immunological and allergies SU 1542415 AZ diseases, in particular, to the method for preparing piperazinyl-containing derivatives of urea or thio · urea of the general formula where R { is hydrogen, trifluoromethyl;
    R ^ is hydrogen, halogen, methyl, methoxy, methylthio, trifluoromethyl, ethoxy / bonyl, cyano;
    R 3 - C ( - C <2 -alkyl, allyl, cyclohexyl, phenyl, unsubstituted or substituted by halogen, lower alkyl, lower alkoxy, carboxyl, lower alkoxycarbonyl, hydroxy, cyano, nitro, lower alkylthio, sulfamide or carbam;
    X is oxygen or sulfur;
    n is 1 to 3; m = 0., 1; p = 2 - 4, or their salts with hydrochloric acid "
    The aim of the invention is to obtain new piperazinyl-containing compounds of the specified General formula with improved, anti-allergic and delaying inflammation properties.
    Example 1. Dihydrochloride 1 ~ [3- (4- (4-chlorobenzip) piperazin-1-yl] propyl] -3-cyclohexylurea.
    A solution of 2.0 g (7.5 mmol) of 1- (3-aminopropyl) -4- (4-chlorobenzyl) piperazine and 1.6 g (12.8 mmol) of cyclohexyl isocyanate in 5 ml of tetrahydrofuran is stirred for 30 minutes at room temperature "The reaction mixture was evaporated under reduced pressure and the remaining oil was dissolved in 10 ml of ethanol." The crude product was precipitated by adding water as a white solid, which was collected by filtration and recrystallized twice from cyclohexane. 1.62 g (56%) of 1 ~ (s ~ p4 -, (4-chlorobenzyl) piperazin-1-yl] p'propyl] -3-cyclohexylurea are obtained in the form of a white crystalline solid. T ”pl.” 109 - 1 12 ° C.
    The product is dissolved in 20 ml of methylene chloride and precipitated in the form of dihydrochloride by adding excess hydrochloric acid. After perekris <
    crystallization from water, the target product is obtained in the form of colorless crystals with so pl. 184 - 187 ° C,
    Example 2 "Dihydrochlorvord
    1- £ 3- £ 4- (4-chlorobenzyl) piperazin-1-yl] propyl] -3-methylurea.
    A solution of 2.68 g (10 mmol) of 1- (3-aminopropyl) -4- (4-chlorobenzyl) piperazine and 0.57 g (10 mmol) of methyl isocyanate in 10 ml of methyl chloride was stirred overnight at room temperature. Reactionary
    20 the mixture is evaporated under reduced pressure and the residue is chromatographed on a column containing silica gel using a mixture of methanol and hydroxide as eluent
    25 aluminum and methylene chloride. Then 1.0 g (31%) of the obtained product is dissolved in 20 ml of a mixture of methylene chloride and ether (1: 1 ratio). The solution is treated with 3Q melt with anhydrous chloride of lm hydrogen. The desired product is obtained in the presence of colorless crystals. T. pl. 193 207 ° C.
    EXAMPLE 3 1- 3- (4- (4-chlorobenzyl) piperazin-1-yl] propyl] -3-n-butylurea hemihydrate of dihydrodichloride 35.
    A solution of 2.67 g of 10 mmol of 1- (3-aminopropyl) -4- (4-chlorobenzyl) pipe4Q razine in 50 ml of methylene chloride and 1.09 g (11 mmol) of n-butyl isocyanate is heated under reflux for 2 hours . The reaction mixture was concentrated in vacuo and the residue was treated with ethereal hydrogen chloride. Recrystallized from a mixture of methylene chloride and methanol. Obtain 3.2 g (71%) of the desired product in addition to colorless crystals. T. pl.
    . 222 - 223 ° C.
    Example 4. Dihydrochlorchloride
    1- £ 3- [4- (4-chlorobenzyl) piperazin-1-yl] propyl] -3-n-hexylurea.
    • Act as described in Example 3, using 3.77 g (10 mmol)
    55 trigvdrohlorvda 1 - (Z-aminrproPil) '; -4- (4-chlorobenzyl) piperazine, 50 ml of tetrahydrofuran, 4.2 ml (30 mmol) of triethylamine and 1.41 g (10 mmol) of n-g of exilizocyanate. By recrystallization from ethanol, 4.00 g (832) of the expected product are obtained in the form of colorless crystals, mp. Mp / 214-215 ° C.
    PRI me R 5 <, Dihydrochloride 1- £ s- [4- (4-chlorobenzyl) piperazin-1-yl] propyl] -3-n-oct ilmourea,
    The procedure described in Example 3 is obtained using 3,77-g (10 mmol) of 1- (3-aminopropyl) -4- (4-chlorobenzyl) piperazine trihydrochloride, 50 ml of tetrahydrofuran, 4.2 ml (30 mmol) of triethylamine and 1 55 g (10 mmol) of n-octyl isocyanate. Recrystallized from a mixture of methanol, ethanol and water. "Obtain 3.1 g (622) of the title compound in white crystals." Mp. 229-230 ° C.
    EXAMPLE 6 Dihydrochlorozzo Monohydrate 1- £ 3 ~ £ 4- (4-fluorobenzyl) piperazin-1-yl] propyl] -3-cyclohexane;
    A solution of 2.0 g (8 mmol) of 1- (3-aminopropyl) -4- (4-fluorobenzyl) piperazine and 1.0 g (8 mmol) of cyclohexyl isocyanate in 20 ml of methylene chloride was stirred overnight at room temperature. The reaction mixture was evaporated and the residue was mixed with 20 ml of ether. The ether solution was filtered, the filtrate was chromatographed on a column containing 300 g of silica gel using the indicated solvent. Product fractions were eluted with a mixture of methylene chloride, methanol and ammonium hydroxide (ratio 45: 5: 1). By evaporation, 2.6 g of (852) 1- {3- £ 4- (4-fluorobenzyl) piperazin-1-yl] propyl] -3-cyclohexylurea are obtained in the form of a light yellow oil. ”The product is dissolved in ether, precipitated with ethereal chloride. recrystallized from hydrogen from ethanol. Get 2.96 g (yield 802) of the indicated compound "T. pl" 203 206 ° C.
    EXAMPLE 7 1- (3- (4-Benzylpiperazin-1-yl) propyl] -3-cyclohexane dihydrochloride dihydrochloride.
    A solution of 2 g (12.9 mmol) * 1- (3-aminopropyl) -4-benzylpiperazine and 1.6 g (12.9 mmol) of cyclohexyl isocyanate in 50 ml of methylene chloride was stirred overnight at room temperature. The reaction mixture is concentrated and the crude product as precipitate dihydrochloride 50
    1542415 6 is obtained from ether in the manner described in Example 6, ”Recrystallized from ethanol to obtain 3.62 g (yield 652) of the title compound as colorless crystals. T "square 202 - 213 ° С.
    Example 8. 1 - [3- (4-Benzylpiperazin-1-ip) propyl] -3-phenylurea.
    A solution of 3.0 g (12, 9 mmol) of 1 ~ (3-aminopropyl) -4-benzylpiperazine and
    1.54 g (12.9 mmol) of phenylisocyanate in 20 ml of methylene chloride are stirred overnight at room temperature. The reaction mixture was concentrated under reduced pressure and the residue was crystallized with aqueous acetone. 2.77 g (612) of the target compound are obtained as colorless. crystals "T" pl, 45 - 47 ° C.
    Example 9. 1- £ 3- {4- (4-Chlorobenzyl) piperazin-1-yl] propyl] -3-phenylurea.
    A solution of 2.0 g (7.5 mmol) of 1- (3-aminopropyl) -4- (4-chlorobenzyl) piperazine and 1.6 g (13.4 mmol) of phenylisocyanate in 5 ml of tetrahydrofuran is stirred for 30 minutes at room temperature. " 5 ml of ethanol is added, the reaction mixture is stirred for 3 hours and dried under reduced pressure. The residue is crystallized with aqueous ethanol. 2.7 g of crude product are obtained. 0.62 g (yield 212) of the title compound are obtained in the form of colorless crystals by recrystallization from the specified solvent. T. pl. 135 - 137 ° C.
    Example 10. Hydrochloride.
    1 - £ 3 - [(4- (4-chlorobenzyl) piperaz.in-1-yl] n yp] -3 - (4-chlorophenyl)
    Example 3 is repeated using 2.67 g (10 mmol) of 1- (3-aminopropyl) -4- (4-chlorobenzyl) piperazine, 50 ml of methylene chloride and 1.54 g (10 mmol) of 4-chlorophenylisocyanate. Recrystallization from methanol gives 1.1 g (252) of the target compound as colorless crystals. T. pl. 241 ° C.
    Example 11 "Dihydrochloride monohydrate 1- £ 3- (4- (4-chlorobenzyl) piperazin-1-yl] propyl] -3- (4-methylphenyl) urea"
    Do as described in example 3, using 2.67 g (10 mmol)
    1- (3-aminopropyl) -4- (4-chlorobenzyl) piperazine, 50 ml of methylene chloride and 1.33 g (10 mmol) of 4-tolyl isocyanate. Recrystallization from a mixture of methanol and methylene chloride gives 0.81 g (17%) of the target compound in stained colorless crystals. T. pl. 131 - 132 ° C.
    PRI me R: er 12. Gitsrochlorsts 1- [z- £ 4- (4-chlorobenzyl) piperaZayn-1-yl] propyl ^ -3- (4-methoxyphenyl) urea.
    The procedure is described as in Example 3, using 0 5.09 g (19 mmol) of 1- (3-aminopropyl) -4- (4-chlorobenzyl) piperazine, 50 ml of methylene chloride and 2.83 g (19 mmol) of 4-methoxyphenyl isocyanate . Recrystallization from a mixture of methanol and methylene chloride afforded 3.57 g (45%) of the target compound in nalt-orange-white crystals, mp. 237 - 238 ° C.
    Example 13. Hydrochlorozz 1 ~ {3- [4- (4-chlorobenzyl) piperazine -1-yl] propyl ^ -3- (4-ethoxycarbonylphenyl) urea.
    The procedure is described as in Example 3, using 7.54 g (20 mmol) of 1 - (3-aminupropyl) -4- (4-chlorobenzyl) piperazine, 50 ml of methylene chloride, 50 ml of terahydrofuran, 8.4 ml (60 mmol) triethylamine and 3.8 g (20 mmol) of 4-ethoxycarbonylphenyl isocyanate. Recrystallization from methanol afforded 3.11 g (34%) of the target compound as colorless crystals. T. pl. 233 - 234 ° C.
    Example 14. 1- £ 3- [4- (4-chlorobenzyl) piperazin-1-yl] propyl ^ 3- (4 ~ fluorophenyl) urea dihydrochloride monohydrate.
    The procedure described in Example 3 is obtained using 3.77 g £ 10 mmol) of 1 - £ 3-aminopropyl) -4- (4-chlorobenzyl) piperazine trihydrochloride, 50 ml of methylene chloride, 10 ml of tetrahydrofuran, 4.2 ml (30 mmol) ) triethylamine and 1.37 g £ 10 mmol) 4-fluorophenylisocyanate. After recrystallization from a mixture of methanol and methylene chloride, 3.75 g (76%) of the target compound are obtained in the form of colorless crystals. T. pl. 225 - 228 ° C.
    Example 15. Dihydrochloride 1 - {3-Pr. (4-chlorobenzyl] 1 piperazin-1-yl] propyl ^ 3- (4-nitrophenyl) urea.
    The procedure described in Example 3 is obtained using 3.77 g (10 mmol) of 1- (3-aminopropyl) -4- (4-chlorobenzyl) piperazine trihydrochloride, 50 ml of tetrazzrofuran, 4.2 ml (30 mmol) of triethylamine and 1, 64 g (10 mmol) of 4-nitrophenyl isocyanate. After recrystallization from a mixture of methanol and water, 2.79 g (55%) of the expected product are obtained in the form of yellow-white crystals. T. pl. 230 - 231 * C (decomposition).
    Example 16. Dighydrochlorozz 1- £ 3- £ 4- (4-chlorobenzyl) homopiperazin-1-yl] propyl ^ -3-cyclohexylurea.
    A solution of 2.16 g (7.7 mmol) of 1- (3-aminopropyl) -4- (4-chlorobenzyl) homopiperazine in 30 ml of methylene chloride and 1.05 g (8.5 mmol) of cyclohexyl isocyanate stirred for 1 h at room temperature. The reaction mixture is concentrated under reduced pressure. The resulting oil is subjected to chromatography on a column containing silica gel (methylene chloride, methanol and ammonium hydroxide in a ratio of 97: 2.5: 0.5). 1- [3- [4- (4-chlorobenzyl) homopiperazin-1-yl] propyl ^ -3-cyclohexylurea is obtained as a colorless oil. This oil is dissolved in ether and precipitated with ethereal hydrogen chloride. 2.25 g (61%) of the target compound are obtained in the form of a white crystalline solid. Mp 167-175 ° C (decomposition).
    Example 17. Dihydrochlorozz 1 - [z- £ 4 - (. 4-chlorobenzyl) homopiperazin-1-wij propyl ^ -3-phenyl-urine.
    1.03 g (3.7 mmol) of 1- (3 ~ aminoproPyl) -4- (4-chlorobenzyl) homopiperazine as described in Example 16 is subjected to exposure to 0.55 g (4.6 mmol) of phenylisocyanate in 15 ml of methylene chloride. The crude product is shredded, purified on silica gel and transferred in the same manner into hydrochloride. 1.23 g (83%) of the target compound are obtained in a vada of colorless crystals. T. pl. 125 - 135 ° C.
    PRI me R 1 benzyl) piperazin-1-yl] propyl-cyclohexylurea.
    '5.36 g (20 mmol) of 1— (3-aminopropyl) -4- (4-chlorobenzyl) piperazine are reacted with 2.82 g (20 mmol) of cyclohexyl isocyanate in 35 ml of chloride for 2 hours as described in Example 16 methylene. Raw
    18. 1- [z- £ 4- (4-Chloro. Λ-39 product is isolated and chromatographed on silica gel in the same way. After recrystallization from ethanol, 2.98 g (36%) of the target compound are obtained as colorless crystals. T pl, 127 - 128 ° C.
    Example 19. 1- £ 3- (4 ~ (4-Chlorobenzyl) piperazin-1-yl] propyl ^ -3-phenylthiourea.
    5.36 g (20 mmol) of 1- (3-aminopropyl) -4- (4-chlorobenzyl) piperazine, as described in Example 16, are reacted with 2.82 g (21 mmol) of phenylisothiocyanate. The crude product is likewise isolated and chromatographed on silica gel. After crystallization from ethanol, 2.39 g (30%) of an off-white crystalline solid are obtained. T. pl. 155 - 156 ° C.
    Example 20. 1- ^ 3- ^ 4- (4-chlorobenzyl) piperazin-1-yl] propyl ^ -3-n-hexylthiourea dihydrochloride hemihydrate.
    A solution of 1.57 g (10 mmol) of n-hexylisothiocyanate in 100 ml of methylene chloride is slowly added to a solution of 3.77 g '(10 mmol) of 1- (3-aminopropyl) -4- (4-chlorobenzyl) piperazine trihydrochloride in 100 ml of methylene chloride and 4.3 ml (31 mmol) of triethylamine. The resulting mixture was heated under reflux for 2 hours, washed with aqueous sodium bicarbonate, dried with sodium sulfate, filtered and the salt precipitated with ethereal hydrochloric acid. After recrystallization from ethanol, 0.80 g (16%) of the target compound are obtained in the form of an off-white powder. , T. pl. 182 - 186 ° C.
    Example 21. 1- £ 3- [4- (4-chlorobenzyl) piperazin-1-yl] propyl ^ -3-b-benzyl urine dihydrochloride.
    The procedure is described in Example 20, using 1.33 g (10 mmol) of benzyl isocyanate, 3.77 g (10 mmol) of 1- (3-aminopropyl) -4- (4-chlorobenzyl) piperazine trihydrochloride, 250 ml of methylene chloride and
    4.3 ml (3 G mmol) of triethylsina. Obtain 3.65 g (77%) of the target compound in the form of colorless crystals, So pl. 203 - 206 ° C.
    i ~
    Example 22. Dihydrochloride | - [3-C4 - (4-chlorophenethyl) piperazin-1-yl] propyl] -3-n-hexylurea.
    A solution of 1.27 g (10 mmol) of n-hex- <silisocyanate in 25 ml of methylene chloride is added to a solution of 2.82 g (10 mmol) of 1- (3-aminopropyl) -4- (4-chlorophenyl) piperazine in 50 ml methylene chloride. The resulting mixture was heated under reflux for 6 hours and concentrated in vacuo. A yellow oil is obtained, which is subjected to silica gel column chromatography (methylene chloride, methanol and ammonium hydroxide in a ratio of 45: 5: 1). After precipitation of the dihydrochloride and recrystallization from ethanol, 0.91 g (19%) of the target compound are obtained in the form of colorless crystals. T. pl. 230 - 233 ° C.
    Example 23. Dihydrochloride Monohydrate 1 - [3- [4- (4-chlorobenzyl) piperazin-1-yl] propyl] -3 ~ (4-cyanophenyl] urea.
    Do as described in example 20, and use 1.44 g. (10 mmol) of 4-cyanophenyl isocyanate, 3.77 g (10 mmol) of 1- (3-aminopropyl) -4- (4-chlorobenzyl) piperazine trihydrochloride, 75 ml of methylene chloride and 4.3 ml (31 mmol) of triethylamine. Recrystallization from a mixture of methanol and ethanol gives
    3.87 g (77%) of the target compound as colorless crystals. T. pl. 236 - 238 ° C.
    Example 24. 1- £ 3- [4- £ 3- (4-chlorophenyl) propyl] piperazin-1-yl] propyl] -3-n-hexylurea dihydrochloride.
    A. 35 g (35 mmol) of triethylamine are slowly added to the mixture of 39 g (0.3 mol) of chloropropylamine hydrochloride, 38.2 g (0.3 mol) of n-hexylisocyanate and 500 ml of methylene chloride. The resulting solution was stirred for .1 h and then the solvent was removed in vacuo. The residue is taken up with ether. The colorless solid is filtered off. The ether solution is washed with water, dried with magnesium sulfate and concentrated. 57.0 g (86%) of pure 1- (3-chloropropyl) -3-n-hexylurea are obtained in the form of colorless crystals. pl. 48 - 50 ° C.
    B. A mixture of 2.21 g (10 mmol) of 1- (3-chloropropyl) propylpiperazine, 1.01 g · (10 mmol) of triethylamine and 25 ml of alcohol is heated under reflux for 18 hours. The cooled reaction mixture was diluted with ether, washed with water, dried with sodium sulfate and concentrated in vacuo. The resulting yellow viscous oil is purified on a column of silica gel (methylene chloride and methanol in a ratio of 93: 7). Precipitation of ethereal hydrochloric acid gives 1.6 g (38%) of the target compound as colorless crystals. T. pl. 21 3 - 216 ° C.
    Example 25. 1 ~ {3- (4- (4-chlorobenzyl) piperazin-1-ylpropyl] -3- (4-acetylphenyl) urine dihydrate dihydrate chloride.
    A solution of 1.61 g (10 mmol) of 4-acetyl1 ″ enylisocyanate in 100 ml of methylene chloride is added to a solution of 3.77 g (10 mmol) of 1- (3-aminopropyl) -4- (4-chlorobenzyl) trihydrochloride piperazine, 50 ml of methylene chloride and 4.3 ml (31 mmol) of triethylamine. The resulting mixture was heated under reflux for 3 hours, washed with aqueous sodium bicarbonate, dried with sodium sulfate and the product precipitated with ethereal hydrochloric acid. After recrystallization from ethanol, 4.13 g (82%) of the target compound are obtained in the form of a white powder, mp. 7197 ° C (slow decomposition).
    Example 26. Dihydrochloride 1 - ^ 3- (4- (4-chlorobenzyl) piperazin-1-yl ^ propyl ^ -Z ^ 4-ethoxyphenyl) urea.
    The procedure described in Example 25 is obtained, using 1.63 g (10 mmol) of 4-ethoxy () enylisocyanate, 3.77 g (10 mmol) of 1- (3-aminopropyl) -4- (4-chlorobenzyl) piperazine trihydrochloride , 16 ml of methylene chloride and 4.3 ml (31 mmol) of triethylamine. . After recrystallization from ethanol, 3.42 g (68%) of the target compound are obtained in the form of colorless crystals. T. pl., 225 - 227 ° C.
    Example 27. Dihydrochloride monohydrate 1- {3- [4- (4-chlorobenzyl) piperazin-1-yl] propyl ^ -3-4- (methylthio) phenyl urea.
    The procedure described in Example 25 is carried out, using 10.0 g (60.5 mmol) of 4- (methylthio) phenylisocyanate, 22.8 g (60.5 mmol) of 1- (3-aminopropyl) -4- (4- chlorobenzyl) piperazine, 400 ml of methylene chloride and 25.8 ml (185 mmol) of triethylamine. After recrystallization from a mixture of methanol and water, 27.3 g (89%) of the target compound are obtained in the form of colorless crystals. T. pl. 212 - 214 ° C <>
    Π r and m’e r 28. 1- {3- [4- (4-chlorobenzyl) piperazin-1-yl] propyl) -3- (4- (methyl10 thio) phenyl] urea dihydrochloride monohydrate.
    Act as described in Example 25, using 1.54 g (10 mmol).
    [2]
    2-chlorophenyl isocyanate,
    [3]
    3.77 g (10 mmol) of 1- (3-ami15 nopropyl) -4- (4-chlorobenzyl) piperazine trihydrochloride I 50 ml of methylene chloride and
    [4]
    4.3 ml (31 mmol) of triethylamine. After recrystallization from methanol, 2.63 g (53%) of the desired compound are obtained in the form of colorless crystals. T. pl. 222 - 224 ° C.
    Example 29. Dihydrochlorozz
    1 - (4- (4- (4-chlorobenzip) piperazint1-yl], propyl ^ -3- (2, 6-dichlorophenyl) urea25.
    The procedure described in Example 25 is carried out using 1.88 g (10 mmol) of 2,6-dichlorophenyl isocyanate, 3.77 g of 30 (10 mmol) of 1- (3-aminopropyl) -4- (4-chlorobenzyl) piperazium trihydrochloride • on, 50 ml of methylene chloride and
    4.3 ml (31 mmol) of triethylamine. After recrystallization from methanol 35, 2.7'5 g (52%) of the target compound are obtained in the form of a colorless crystal. fishing, T. pl. 246 - 248 ° C ,,
    Example 30. Dihydrochloride
    1 - (4- (4- (4-chlorobenzyl) piperisin-140-yl] propyl ^ g-3- (n-dodecyl) urea.
    The procedure described in Example 25 is obtained using 2.11 g (10 mmol) of n-dodecyl isocyanate, 3.7 7 g (10 mmol) of 1- (3-aminopropyl) 45 -4- (4 ~ chlorobenzyl) piperazine trihydrochloride, 100 ml methylene chloride and 3.03 g (30 mmol) of triethylamine. After recrystallization from water, 3.21 g (58%) of the target compound are obtained in the form of 50 colorless crystals. T. pl. 215 222 ° C <,
    Example 31. Dihydrochloride
    1- [3- {4- (4-chlorobenzyl) piperazin-255-yl] propyl [- 3- (4-carbamylphenyl) urea.
    A solution of 10.0 g (19.9 mmol) of dihydrochlorchloride monohydrate 1- [s - [^ 4- (4-chlorobenzyl) piperazin-1-yl] propyl ^ 13 15
    -3- (4-cyanophenyl) urea, 1 20 ml of glacial acetic acid and 80 ml of concentrated hydrochloric acid are heated at 80 ° C for 30 minutes. The mixture is poured onto ice and made basic with aqueous potassium hydroxide. The product is extracted with methylene chloride, dried with sodium sulfate and the salt precipitated with ethereal hydrochloric acid. Recrystallized several times from. ethanol and get 3.54 g (38%) of the target compound as colorless crystals. T. pl. 224 - 226 ° C.
    Example 32, Dihydrochloride 1 -] (3- (4- (4-chlorobenzyl) piperazin-1-yl] propyl] -3- (4-tert-butylphenyl) urea.
    A solution of 4.22 g (20 mmol) of 3-iodopropylisocyanate in 25 ml of ether is added to a solution of 2.98 g (20 mmol) of 4-tert-butylaniline in 25 ml of ether. The resulting solution was heated under reflux for 3 hours. After removing the solvent, 4.18 g (20 mmol) of 4-chlorobenzylpiperazine in 50 ml of ethanol are added. The resulting solution was heated to reflux for 24 hours. a refrigerator. Aqueous sodium bicarbonate was added to the mixture, and then the product was extracted with methylene chloride, dried with sodium sulfate and the salt precipitated with ethereal hydrochloric acid. After repeated recrystallization with ethanol, 3.73 g (33%) of the target compound are obtained in the form of colorless crystals. T. pl. 240 - 241 ° C.
    Similarly to examples 1-32 receive the following compounds:
    hydrochloride 1 - [3 - [] 4- (4-chlorobenzyl) piperazin-1-yl] propyl] -3- (4-carboxyphenyl) urine, mp 2444246 ° С, 48% yield (l);
    1- [3- [4- (3-three}) tormethyl-4-chlorobenzyl) piperazin-1-yl] propyl] -3-n-hexylurea dig. 216-219 ° C, yield 35% (il);
    dihydrochlorozzo monohydrate 1- [z ~ [4- [3- (4-chlorophenyl) propyl] piper • din-1-yl] propyl] -3- (4-cyanophenyl) urea, mp 219-221 ° C, yield 29% (III);
    dihydrochloride 1- (3- (4- (4-chlorobenzyl) yp eraz in-1-yl] prop yl] 3 -all urea, mp 232-234 ° С, 50% yield (IV );
    [5]
    5'
    15 i4 dihydrochloride 1- (3- (4- (4-chlorobenzyl) piperazin-1-yl] propyl} -3- (3-ethoxycarbonylphenyl) urea, ”t” pl. 240 · 243 ° С, 34% yield (v );
    1- (3 - [(4- (4-chlorobenzyl) piperazin-1-yl] propyl] 3- (3 hydroxy-4-ethoxycarbonylphenyl) urea dihydrochloride,
    t. pl. 245-247 ° C, yield 21% (VI);
    1- (z - ((4- (4-cyano-benzyl) piperazin-1-yl] propyl] -3- (4-cyanophenyl) urea monohydrate, Urea, pl. 220-223 ° С, 26% yield (VII);
    dihydrochloride 1- (3- (4- (4-chlorobenzene Opiper ^ in-! -yl] propyl) -3- (4-sulfmylphenyl) urea, mp 245-246 ° С, 31% yield (VIII);
    dihydrochloride 1- {3 - {(4- (4-cyanobenzyl) piperazin-1-yl] propyl] ~ 3- (4-ethoxycarbonylphenyl) urea, mp 241-245 ° С, yield 46% ~ (1X );
    dihydrochloride 1 - ((3 - ((4- (4-labels-sibenzyl) piperazin-1-yl] propyl] 3- (4-ethoxycarbonylphenyl] urea, - 't "pl. 215-218 ° С, yield 43 % (x);
    dihydrochlorozzo monohydrate 1- £ 3 .- ((4- (4-methylthiobenzyl) piperazin-1-yl] p op yl] -3 - (4 - this is ik a rb onylphenyl) urea, mp 200- 222 ° C, yield 39% (Xi);
    1- {3— - (4- (4-methylbenzyl) piperazin-1-yl] propyl] -3- (4-ethoxycarbonylphenyl) 1 hydrochloride monohydrate urea, mp 226-229 ° С, 37% yield (XII );
    1- [3 - ((4- (3-trifluoromethylbenzyl) piperazin-1-yl]] propyl] -3- (4-ethoxycarbonylphenyl) urea dihydrochloride monohydrate, mp 240-243 C, 22% yield (XIIl) ;
    1- (3- (4- (4-ethoxycarbonylbenzyl) piperazin-1-yl] propyl] -3- (4-ethoxycarbonylphenyl) urea dihydrochloride monohydrate, mp 235237 ° С, 26% yield (XTV);
    dihydrochloride 1 - (^ 2- (4- (4-chlorobenzyl) piperazin-1-yl) propyl-3- (4-cyanophenyl) urea, mp 217—219 ° С, yield 35% (XV);
    dihydrochloride hemihydrate 1 - (- 4 - ((4- (4-chlorobenzyl) piperazin-1-yl] butyl] -3- (4-ethoxycarbonylphenyl) mo, chevins, mp 227-228 ° С, yield
    39% / XVI);
    urea dihydrochloride monohydrate 1- (3 - ((4- (4-chlorobenzyl) piperazin-1-yl-propyl | -3- (4-methoxycarbonyl)), mp 205-208 ° C, 25% yield (XVII);
    1- ^ 4- (4- (4-chlorobenzyl) piperazin-1-yl ^ bTHnj-3- (4-cyanophenyl) urea dihydrochloride monohydrate, mp 203-212 ° С, 42% yield (XVIII);
    1- [3- [4- (4-chlorobenzyl) piperazin-1-yl-Dpropyl ^ -Zt (4-hydroxyphenyl) urea dihydrochloride monohydrate, mp 224-228 ° C, yield 40% (X1X);
    . dihydrochloride 1 - {3 ~ C4- (4-chloro benzene) piperazin-1-yl] propyl-3- (4-isopropoxycarbonylphenyl urea, mp 230-232 ° C, 31% yield: (XX); ' d digscrochlordwa monohydrate 1- {2-.
    - (4- (4-chlorobenzyl) piperazin-1-yl} ethyl} -3 - (, 4-ethoxycarbonyl) urea, j mp 218-219 * 0, yield 36% (XXl);
    1- (3- [4- (4-chlorobenzyl) piperazin-1-yl)] propyl ^ -3- (4-n-butoxycarbonylphenyl) · urea monohydrate dihydrochloride, urea, mp 205-207 ° С, 32% yield (Xxii); · Dihydrochloride hemihydrate 1- {z - (/ - (3-chlorobenzyl piperazin-1-yl2propyl ^ -3- (4-ethoxy and carbonylphenylureas, mp 23O-232 ° С, 29% yield (XXIII).
    The higher activity of the new piperazinyl-containing compounds compared to the known compound is confirmed by the results of an experiment to determine the concentration providing 50% inhibition (KTjq) of histamine release from human leukocytes.
    The results are tabulated.
    Compound CT 50 , j * M 2. Following the example one fifty 2 300 3 fifty four 8 5 16 6 fifty 7 240 8 400 9 ' 78 10 thirty eleven 37 12 80 13 190
    Table continuation
    one one ...oneoneoneoneoneone| aoneoneoneone fourteen twenty fifteen thirty 16 OF 17 115 eighteen 26 19 37 21 112 22 16 23 81 ’24 10 25 115 26 35 27 fifty 28 > 100 29th 29th thirty 40 31 150 I 300 II 320 III twenty IV 120 V 59 VII > 100 X 55 Xi 210 XVII 35 XV 41 XVIII 27 XIX 370 XX ' 140 XXI 59 XXII 32- . XVI 27 XII 64 XXIII 34 Cyanarizine (known) 1000
    The new compounds have the same toxicity as the known compound, ie>> 100 mg / kg (oral, mouse).
    The results, tables indicate a higher antiallergic activity of these * compounds. Experience in determining the inhibition of histamine excretion from white blood cells of 55 people in vitro.
    To 1.0 ml suspension of white blood cells' .cheloveka (2-Yu 6 cells) in a buffer system Tris-ACM added 0.05 ml antigen (anti-human globulin immuno17 E) and 0.2 ml of water containing the active substance in various concentrations. The reaction mixture was incubated at 37 ° C for 60 minutes, after which it was centrifuged and the supernatant was collected. Protein is removed from the supernatant by precipitation of 0.2 ml of 8% perchloric acid. Histamine release is measured by fluorometry and its percentage inhibition is calculated by the following formula :. .
    control medium - medium with active substance control medium
    In this case, the concentration of the active substance, providing 50% inhibition of histamine release (CT ^), is determined by interpolation according to the diagram of percent inhibition and the logarithm of the concentration of the active substance.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1542415A3|1990-02-07|Method of producing piperasinyl-containing derivatives of urea or thiourea, or their salts with hydrochloric acid
    DK145297B|1982-10-25|METHOD OF ANALOGUE FOR THE PREPARATION OF 2H-1,2-BENZOTHIAZINE-1,1-DIOXIDE DERIVATIVES OR TAUTOMERS OR BASAL SALTS THEREOF
    CS200545B2|1980-09-15|Method of producing derivatives of guanidine
    KR100758775B1|2007-09-14|Five-membered-ring Compound
    DE69828276T2|2005-12-15|New cyclic diamine compounds and remedies containing them
    HU188697B|1986-05-28|Process for producing 2,4-disubstituted thiazole derivatives
    WO2005042505A1|2005-05-12|Thiozolidinones, production and use thereof as medicaments
    HU179492B|1982-10-28|Process for producing 1,2,4-thiadiasole derivatives
    US4496571A|1985-01-29|Histamine H2-antagonists
    HU205922B|1992-07-28|Process for producing thiazol derivatives and pharmaceutical compositions containing them
    US4057632A|1977-11-08|Method of treatment using tetrazole-5-carboxamide derivatives
    US4464374A|1984-08-07|Substituted guanidine derivatives, processes, pharmaceutical compositions and methods and intermediates
    US4795755A|1989-01-03|Heterocyclic derivatives
    EP0649843B1|2000-09-06|Thiazoline derivative
    US4451463A|1984-05-29|Alcohol derivatives
    FI63937B|1983-05-31|FREQUENCY REQUIREMENT FOR THERAPEUTIC USE OF THERAPEUTIC TREATMENT
    US4548935A|1985-10-22|Dihydropyridine anti-ischaemic and anti-hypertensive agents, compositions and use
    US4705787A|1987-11-10|Quinazolinone derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
    US4261994A|1981-04-14|1,2,4-Oxadiazole derivatives, their preparation and pharmaceutical use
    EP0055917B1|1984-11-21|New benzothiazine derivatives, processes for preparation thereof and use thereof
    DE2429195A1|1976-02-05|2-Amino-pyrazolo-|-thiazoles useful as dye inters - prepd. by ring-closing dehydrogenation of substd. pyrazolyl thioureas
    JP2003192591A|2003-07-09|Medicine composed of 5-membered ring compound
    JP2003201271A|2003-07-18|Lipid modulator
    FI77238B|1988-10-31|FOERFARANDE FOER FRAMSTAELLNING AV PHARMACOLOGISKT VAERDEFULLA PHENYLALKYL | ALKYLTIOLER ELLER THIOCARBAMATER.
    US5246927A|1993-09-21|Benzazole derivatives, processes for their preparation containing such compounds and the use thereof
    同族专利:
    公开号 | 公开日
    JPH0469147B2|1992-11-05|
    DK160554B|1991-03-25|
    NO161618B|1989-05-29|
    FI76327B|1988-06-30|
    IL72123D0|1984-10-31|
    NZ208535A|1987-02-20|
    IE59034B1|1993-12-15|
    AU565041B2|1987-09-03|
    KR890000175B1|1989-03-09|
    CA1219260A|1987-03-17|
    FI76327C|1988-10-10|
    PL248207A1|1985-08-13|
    EP0129207B1|1988-03-16|
    NO842417L|1984-12-17|
    PL146314B1|1989-01-31|
    FI842408A0|1984-06-14|
    DK294084D0|1984-06-15|
    GR82367B|1984-12-13|
    IE841499L|1984-12-16|
    KR850000422A|1985-02-27|
    AT33023T|1988-04-15|
    PT78729A|1984-07-01|
    EP0129207A3|1985-07-31|
    EP0129207A2|1984-12-27|
    PT78729B|1986-10-21|
    PH24059A|1990-03-05|
    ES533448A0|1985-08-01|
    YU104584A|1986-12-31|
    JPS6075469A|1985-04-27|
    YU150186A|1987-06-30|
    ZA844527B|1986-02-26|
    HUT34464A|1985-03-28|
    AU2940484A|1984-12-20|
    FI842408A|1984-12-17|
    PL147413B1|1989-05-31|
    ES537662A0|1985-09-16|
    NO161618C|1989-09-06|
    ES8506651A1|1985-08-01|
    ES537661A0|1985-11-01|
    DK294084A|1984-12-17|
    DE3469896D1|1988-04-21|
    PL252851A1|1986-07-01|
    ES8600255A1|1985-09-16|
    DK160554C|1991-09-09|
    ES8601928A1|1985-11-01|
    CS244821B2|1986-08-14|
    HU192409B|1987-06-29|
    IL72123A|1987-09-16|
    AR242377A1|1993-03-31|
    SU1387877A3|1988-04-07|
    DD223710A5|1985-06-19|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    WO2010096011A1|2009-02-20|2010-08-26|Astrazeneca Ab|Cyclopropyl amide derivatives targeting the histamine h3 receptor|
    US9012452B2|2010-02-18|2015-04-21|Astrazeneca Ab|Processes for making cyclopropyl amide derivatives and intermediates associated therewith|
    US9029381B2|2007-08-22|2015-05-12|Astrazeneca Ab|Cyclopropyl amide derivatives|
    US10934282B2|2016-07-13|2021-03-02|Leo Pharma A/S|Heteroaromatic modulators of the retinoid-related orphan receptor gamma|
    US4661481A|1983-06-16|1987-04-28|Boehringer Ingelheim Pharmaceuticals, Inc|Substituted phenylalkylhomopiperazinylpropyl useful for treatment of immulogical, inflammatory and allergic disorders|
    FR2601366B1|1986-07-10|1988-11-25|Andre Buzas|BENZHYDRYLOXYETHYL-PIPERAZINE DERIVATIVES, PROCESSES FOR OBTAINING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.|
    JP2722250B2|1989-05-30|1998-03-04|興和株式会社|Novel diamine compound and cerebral dysfunction improving agent containing the same|
    JPH0525145A|1991-07-15|1993-02-02|Mochida Pharmaceut Co Ltd|Agent for treatment of allergic disease|
    JP3719612B2|1993-06-14|2005-11-24|塩野義製薬株式会社|Urea derivatives containing heterocycles|
    ITRM20060090A1|2006-02-22|2007-08-23|Sigma Tau Ind Farmaceuti|NEW COMPOUNDS CPT INHIBITORS AT LEVEL OF THE SNC AS ANTI-DIABETIC AND OR ANTI-BESIDE DRUGS|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US50483783A| true| 1983-06-16|1983-06-16|
    [返回顶部]